Holen Sie sich die Stockscreener-App
58.35
0.19%
-0.11
Vorhandelsmarkt:
57.85
-0.50
-0.86%
Schlusskurs vom Vortag:
$58.46
Offen:
$58.88
24-Stunden-Volumen:
149.39K
Relative Volume:
0.62
Marktkapitalisierung:
$1.22B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
71.16
EPS:
0.82
Netto-Cashflow:
$100.45M
1W Leistung:
+7.74%
1M Leistung:
+9.37%
6M Leistung:
-6.17%
1J Leistung:
+5.31%
1-Tages-Spanne:
$57.98
$59.26
1-Wochen-Bereich:
$54.75
$59.26
52-Wochen-Spanne:
$52.50
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
58.35 | 1.22B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
Millennium Management LLC's Strategic Acquisition in ANI Pharmac - GuruFocus.com
ANI Maintains Course With Rare Disease Push In 2025 - News & Insights
Wedge Capital Management L L P NC Reduces Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Declines By 8.5% - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) delivers shareholders respectable 12% CAGR over 3 years, surging 6.2% in the last week alone - Simply Wall St
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? - Yahoo Finance
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock - MarketBeat
Ani Pharmaceuticals senior VP sells $21,568 in stock By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals senior VP sells $21,568 in stock - Investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week LowHere's What Happened - MarketBeat
Alcami Announces CEO Transition - Quantisnow
ANI Pharmaceuticals Projects Strong Growth for 2025 - TipRanks
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 - Marketscreener.com
ANI Pharmaceuticals Projects Strong 25% Growth for 2025, Exceeds 2024 Guidance Targets - StockTitan
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook - GlobeNewswire
ANI Continues To Spearhead FDA’s CGT Path With Prucalopride Launch - Citeline
JPMorgan Chase & Co. Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity - Marketscreener.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity - The Manila Times
ANI Pharmaceuticals Launches First Generic Motegrity with Exclusive 180-Day Market Access - StockTitan
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Rises By 27.7% - Defense World
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ANI Pharmaceuticals CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Consensus Target Price from Analysts - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Reduced by Wellington Management Group LLP - MarketBeat
State Street Corp Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock By Investing.com - Investing.com Nigeria
Insider Sell: Stephen Carey Sells 7,500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus.com
Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock - Investing.com
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares - Simply Wall St
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Barclays PLC - MarketBeat
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock - Investing.com
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock By Investing.com - Investing.com Australia
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.03 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Key Pharmaceutical Suspension Market Trend 2024-2033: ANI Pharmaceuticals Launches Kionex Suspension - EIN News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decrease in Short Interest - MarketBeat
Insider Sell: Krista Davis Sells 1,000 Shares of ANI Pharmaceuti - GuruFocus.com
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of ANI Pharmaceuticals (ANIP) with Outperform Recommendation - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Leerink Partners - MarketBeat
Where ANI Pharmaceuticals Stands With Analysts - Benzinga
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):